Global Immune Technologies Completes Securities Agreement with Primedical, Elects New Board of Directors

Vancouver, Canada, August 15, 2006 - Global Immune Technologies, Inc. (GIMU:OTCBB), is pleased to advise that it has signed a Securities Exchange Agreement (SEA) proposing a reverse merger with Primedical International Limited (PML). The combined company, to be renamed Primedical International Holdings, Inc. (Primedical), intends to be a leading provider of telemedicine and remote ambulatory monitoring services.

GIMU will acquire PMI’s ambulatory ECG monitoring business, including iCardia Healthcare Corporation, the North American cardiac monitoring service, for a combination of convertible debt and equity. Specifically, PML will receive 74 million common shares in GIMU, together with 7.4 million warrants with a purchase price of $0.50. In addition, the agreement provides for the transfer of intellectual property from Medical Monitors Limited (MML), an Australian Stock Exchange listed company, subject to ratification by MML shareholders. In further consideration, GIMU shall issue PML and MML a total of $14 million non interest bearing notes, convertible into GIMU common shares at 85% of the average closing price for the 5 business days preceding conversion, but no less than $0.40 and no greater than $1.00 per share.

Primedical plans to rapidly grow its current business in North America through its subsidiary iCardia Healthcare Corporation, and to expand into Europe and the Far East through strategic joint ventures and/or acquisition of regional monitoring service companies.

To lead the Company’s expansion into telemedicine and remote ambulatory monitoring services three new directors are joining the GIMU/Primedical board: David Stanley, current CEO of iCardia Healthcare Corporation; Harry Platt, co-inventor of the Company’s proprietary systems and innovative technology, and Avraham Perez, CPA, MBA and co-founder of a successful data analytics company in the US health insurance sector.

David Stanley, Chief Executive Officer
Mr. Stanley is currently CEO of iCardia and has over 26 years experience in the US medical devices distribution sector. Previously, he built his own distribution company, Park Plaza Southwest Inc, which in 1993 merged with Taylor Medical Inc, where he was responsible for sales and marketing, overseeing over 180 sales representatives. In 1995 Taylor Medical was bought by PSS, the largest supplier of medical products to physicians in the US. Mr. Stanley will continue to lead iCardia.

Harry Platt, Chief Technology Officer
Mr. Platt is the inventor and co-developer of the cardiac monitoring technologies licensed by iCardia. He has developed the world’s smallest diagnostic quality cardiac monitor and is the inventor of numerous patented medical technologies. Mr. Platt has more than 25 years experience in the development and management of technology projects.

Avraham Perez
Mr. Perez is a qualified Certified Practicing Accountant, and was previously the Finance Manager with State Street Banking Corporation for the Asia Pacific region. In 1999 Mr. Perez completed his MBA at Yale University, and has since co-founded a successful company specialized in health data analytics in the health insurance industry.




About iCardia Healthcare Corporation
Through innovative technologies licensed from MML, iCardia is the lowest cost cardiac monitoring service provider in the market. iCardia’s Single Use Patient Event Recorder (SUPER) is a lightweight, simple to use monitor that boosts patient compliance, is absolutely hygienic, and delivers high quality cardiac data. The service receives the transmitted data and produces reports that can be viewed, annotated, and stored electronically, enhancing analysis, interpretation, and mean time to diagnosis.

Cardiac Monitoring Market
Frost & Sullivan have estimated that the US market for monitoring devices in 2004 was worth US$296million and that the associated services market was worth US$3.24 billion.

According to the American Heart Association (AHA), 14 million Americans are believed to have a history of intermittent heart rhythm disorders and, of those, only 4 million have been diagnosed.

Forward-Looking Statements
Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. You should independently investigate and fully understand all risks before making investment decisions.

Contact Information
Harry Platt
+1 (203) 654-7093
hplatt@primedical.com


www.primedical.com
www.icardia.com